Allakos Inc. (NASDAQ:ALLK) Shares Sold by Barclays PLC

Barclays PLC lowered its position in shares of Allakos Inc. (NASDAQ:ALLK) by 23.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 869,969 shares of the company’s stock after selling 264,049 shares during the period. Barclays PLC’s holdings in Allakos were worth $568,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Point72 Asset Management L.P. acquired a new stake in Allakos in the third quarter valued at $1,143,000. FMR LLC increased its holdings in shares of Allakos by 14.6% in the 3rd quarter. FMR LLC now owns 5,370,247 shares of the company’s stock valued at $3,508,000 after acquiring an additional 685,623 shares during the last quarter. Acadian Asset Management LLC raised its position in shares of Allakos by 32.4% during the 2nd quarter. Acadian Asset Management LLC now owns 1,762,814 shares of the company’s stock worth $1,761,000 after acquiring an additional 431,175 shares in the last quarter. RBF Capital LLC raised its position in shares of Allakos by 45.9% during the 3rd quarter. RBF Capital LLC now owns 510,529 shares of the company’s stock worth $333,000 after acquiring an additional 160,529 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Allakos during the second quarter worth approximately $112,000. Institutional investors and hedge funds own 84.64% of the company’s stock.

Allakos Price Performance

NASDAQ ALLK opened at $1.21 on Thursday. The company has a fifty day moving average of $1.16 and a two-hundred day moving average of $0.91. The company has a market capitalization of $108.11 million, a PE ratio of -0.60 and a beta of 0.92. Allakos Inc. has a 1 year low of $0.54 and a 1 year high of $3.36.

Allakos (NASDAQ:ALLK) last announced its earnings results on Wednesday, November 6th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.01. On average, research analysts expect that Allakos Inc. will post -1.16 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, JMP Securities reiterated a “market outperform” rating and issued a $3.00 price target on shares of Allakos in a research note on Thursday, September 26th.

Allakos Profile

Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.